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Abstract
Myotubularin MTM1 is a phosphoinositide (PPIn) 3-phosphatase mutated in X-linked centronuclear myopathy (XLCNM;
myotubular myopathy). We investigated the involvement of MTM1 enzymatic activity on XLCNM phenotypes. Exogenous
expression of human MTM1 in yeast resulted in vacuolar enlargement, as a consequence of its phosphatase activity.
Expression of mutants from patients with different clinical progression and determination of PtdIns3P and PtdIns5P cellular
levels confirmed the link between vacuolar morphology and MTM1 phosphatase activity, and showed that some disease
mutants retain phosphatase activity. Viral gene transfer of phosphatase-dead myotubularin mutants (MTM1C375S and
MTM1S376N) significantly improved most histological signs of XLCNM displayed by a Mtm1-null mouse, at similar levels as
wild-type MTM1. Moreover, the MTM1C375S mutant improved muscle performance and restored the localization of nuclei,
triad alignment, and the desmin intermediate filament network, while it did not normalize PtdIns3P levels, supporting
phosphatase-independent roles of MTM1 in maintaining normal muscle performance and organelle positioning in skeletal
muscle. Among the different XLCNM signs investigated, we identified only triad shape and fiber size distribution as being
partially dependent on MTM1 phosphatase activity. In conclusion, this work uncovers MTM1 roles in the structural
organization of muscle fibers that are independent of its enzymatic activity. This underlines that removal of enzymes should
be used with care to conclude on the physiological importance of their activity.
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Introduction
X-linked centronuclear myopathy (XLCNM, also called
myotubular myopathy; OMIM 310400) is a recessive congenital
muscle disorder affecting mainly males and due to mutations in the
MTM1 gene coding for the phosphoinositides (PPIn) phosphatase
myotubularin [1]. The most severe form of XLCNM is
characterised by hypotonia at birth, muscle atrophy, generalized
muscle weakness and respiratory failure leading to high neonatal
mortality [2]. Milder clinical phenotypes and progression were
also reported and some are compatible with nearly normal lifespan
[3]. Muscle biopsies from XLCNM patients show hypotrophic
muscle fibers with an abnormal central positioning of nuclei. A
mouse model lacking the MTM1 protein (Mtm1 KO) has been
characterized and reproduces the muscle mass decrease and most
histopathological features of XLCNM, including muscle fibers
hypotrophy and abnormal organelles positioning [4]. While the
MTM1 gene is ubiquitously expressed, skeletal muscle is the tissue
mainly affected. To date almost 200 different disease-causing
mutations have been identified in the MTM1 gene [3,5–7]. Most
mutations cause severe forms of the myopathy characterized by a
strong decrease in the protein level, at least in fibroblasts or
lymphoblasts, whereas others cause milder forms of the disease
[8,9]. A very mild XLCNM phenotype was even described in a
67-year-old grandfather with a N180K missense mutation [3].
However, the genotype-phenotype correlation is not extensive and
the importance of the PPIn phosphatase activity in the disease
phenotype was not defined.
Myotubularin (MTM1) displays PPIn 3-phosphatase activity
and converts phosphatidylinositol 3-phosphate (PtdIns3P) into
PtdIns and phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2)
into PtdIns5P. The PtdIns3P phosphatase activity of myotubularin
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was identified in a purified protein complex in brain and
confirmed in vitro and ex vivo after the isolation of the cDNA
[10,11]. The catalytic site and mechanism of MTM1 resembles
those of dual-specificity protein phosphatases. Indeed, mutation of
the catalytic cysteine of MTM1 into serine (C375S, phosphatase-
dead) totally abolished its enzymatic activity [12–14]. PtdIns3P
produced by the PtdIns 3-kinase hVPS34/Vps34, is enriched at
early and late endosomes and is essential for endosomal protein
sorting and trafficking, autophagy and proper morphology of the
endosomal compartment in human and yeast cells (for a review see
[15]). PtdIns3P is also produced by class II PtdIns 3-kinases in
multicellular eukaryotes, while these kinases are absent in yeasts
[16,17]. PtdIns(3,5)P2, the other substrate of MTM1, is generated
from PtdIns3P by the 5-kinase PIKfyve/Fab1. The absence of
PtdIns(3,5)P2 resulting from impairment of PIKfyve activity in
mammalian cells, or from FAB1 gene deletion in yeast S. cerevisiae,
leads to a swollen or enlarged endosomal/lysosomal compartment
associated with retrograde endosomal trafficking defects (for a
review see [18]).
The study of MTM1 in human cells is hampered by the
presence of highly conserved paralogues, termed MTMR for
myotubularin related proteins. There are thirteen MTMR
proteins (MTMR1 to MTMR13), seven of which are active
phosphatases while the other six are dead phosphatases lacking key
catalytic residues. S. cerevisiae contains only one member of the
myotubularin family, Ymr1 (yeast myotubularin related-1) encod-
ed by the YJR110W gene [19,20]. Ymr1 displays PtdIns 3-
phosphatase activity in vitro and in vivo and deletion of the YMR1
gene leads only to minor phenotypes [12,21].
The aim of this study is to understand the importance of the
MTM1 PPIn phosphatase activity in the phenotype and severity of
the disease. We first analyzed at the cellular level the functional
impact of MTM1 mutations isolated from patients using yeast S.
cerevisiae ymr1D deletion strains. Among the described mutations in
MTM1, we have chosen to enzymatically characterize missense
mutations affecting different MTM1 domains that lead to severe,
mild or very mild XLCNM forms. We then analyzed the
morphology of the vacuolar/lysosomal compartment, the subcel-
lular distribution of these proteins and the intracellular levels of the
different PPIn. The yeast results show that some disease mutants
display phosphatase activity. In parallel, we performed rescue
experiments for the XLCNM-like phenotypes displayed by the
Mtm1 KO mice using adeno-associated viral gene transfer of
murine wild-type, phosphatase-inactive C375S or S376N con-
structs. Taken together, our data show that phosphatase-dead
MTM1 mutants ameliorated most phenotypes of knock-out mice
thus suggesting that myotubularin displays phosphatase-indepen-
dent functions to maintain normal skeletal muscle.
Results
Expression of human Myotubularin MTM1 in yeast
impairs vacuolar morphology
We analyzed in yeast S. cerevisiae the expression of four missense
mutations in MTM1, two affecting the PPIn interaction PH-
GRAM domain (MTM1V49F and MTM1R69C), one the protein-
protein interaction domain RID (MTM1N180K) and one the
phosphatase catalytic domain (MTM1R421Q), leading respectively
to severe, mild or severe (depending on the family), very mild, and
severe XLCNM forms (Figure 1A) [3,5,6,22]. We used as controls
the wild-type MTM1 and the artificial phosphatase-dead
MTM1C375S mutant [12]. The different MTM1 constructs were
expressed into the ymr1D yeast mutant from either low (CEN) or
high (2 m) copy number plasmids. Growth curves (optical density
of liquid cultures as a function of time) as well as drop tests
revealed that none of the plasmids induced a significant growth
defect and that only cells expressing MTM1 or MTM1R69C
showed a slight growth delay (Figure S1). The Western blot
analysis shows that the different human MTM1 proteins were
produced at the expected molecular weight (70 kDa) and that
protein levels in cells transformed with CEN plasmids were lower
than in cells transformed with 2 m plasmids (Figure 1B). None-
theless, there were differences in the levels of the different MTM1
produced. Indeed, mutants having little or no effect on growth,
like the phosphatase-dead MTM1C375S, were most abundant
while mutants delaying growth, like MTM1R69C, were least
abundant suggesting that yeast cells regulate the production of the
exogenous human proteins.
The expression of MTM1 in fission yeast Schizosaccharomyces
pombe induced an enlarged vacuolar phenotype [13,23]. This was
also observed upon expression of MTMR3 in S. cerevisiae and the
enlarged vacuolar phenotype was correlated with MTMR3 PPIn
3-phosphatase activity [24]. We stained the vacuolar membrane
with the lipophilic fluorescent dye FM4-64 in ymr1D cells upon
MTM1 or MTM1C375S production (pVV204, CEN) or overpro-
duction (pVV200, 2 m). Wild-type yeast cells show unilobar
vacuoles, whereas the ymr1D mutant displayed small multilobar
vacuoles (Figure 2). In contrast, MTM1 overproduction resulted in
larger cells with a small or large unilobar vacuole, whereas
MTM1C375S overproduction resulted in no obvious change in cell
morphology (Figure 2A). The vacuolar morphologies were
classified by microscopic observation into three categories: large
unilobar or giant, small one or two lobes and more than two lobes
or fragmented vacuoles (Figure 3). A significantly higher percent-
age of cells with abnormally large vacuoles was observed upon
MTM1 production and this was increased with overproduction,
whereas this percentage was low for MTM1C375S and similar to
the empty plasmid controls (Figure 3).
Author Summary
X-linked centronuclear myopathy is a muscle disorder
characterized by neonatal hypotonia and abnormal
organelle positioning in skeletal muscle. This myopathy is
due to different mutations in the MTM1 gene encoding
the phosphoinositide phosphatase myotubularin. Disease-
causing mutations are found all along the protein
sequence and not only in the phosphatase catalytic
domain. We investigated the link between myotubularin
phosphatase activity and disease phenotypes. We used
brewer yeast as a simple cellular model to analyze the in
vivo phosphatase activity of different disease mutants. Our
results show that mutations responsible for severe forms
of myopathy are either active or inactive phosphatases. To
further question this finding, we used the mice myotubu-
larin knock-out model that reproduces faithfully the
histopathological findings from human patients. Expres-
sion of phosphatase-dead mutants improved most phe-
notypes of knock-out mice comparable to wild-type
myotubularin. This shows that the maintenance of normal
skeletal muscles is largely independent from myotubularin
phosphatase activity, while defects in the activity may
participate in the onset of the disease. Moreover, it could
have important implications in the design of therapeutic
approaches aimed at manipulating the phosphoinositide
levels in the different diseases linked to myotubularin
homologues. Finally, these data call for cautiousness when
manipulating such enzymes to conclude on the physio-
logical relevance of their activity.
Phosphatase-Independent Roles of Myotubularin
PLOS Genetics | www.plosgenetics.org 2 October 2012 | Volume 8 | Issue 10 | e1002965
The enlarged vacuole phenotype could be due to the 3-
phosphatase activity of MTM1 or to loss of Fab1 kinase functions
upon MTM1 production. Indeed, the fab1D mutant also displays
the enlarged vacuole phenotype (Figure 2A) [25]. Osmotic stress in
wild-type yeast results in vacuolar fragmentation (Figure 2A), due
to stimulation of Fab1 kinase activity [26,27]. The ymr1D cells
producing either MTM1 or phosphatase-dead MTM1C375S
displayed fragmented vacuoles upon osmotic shock, whereas in
the fab1D mutant vacuoles remained enlarged (Figure 2A),
indicating that overproduction of MTM1 did not block the Fab1
kinase activity. A similar result was previously obtained with S.
cerevisiae cells expressing human MTMR3 [24]. These results show
that MTM1 phosphatase activity is directly responsible for the
enlarged vacuole phenotype observed in yeast cells. Thus, analysis
of vacuolar morphologies can be used to assess the MTM1
enzymatic activity of mutants found in XLCNM patients.
Differential impact of XLCNM patient MTM1 mutations
on yeast vacuolar morphology
The vacuolar morphology of the ymr1D mutant expressing or
overexpressing the four MTM1 constructs with XLCNM muta-
tions was analyzed (Figure 1A). Many cells producing MTM1V49F,
MTM1R69C and MTM1N180K displayed enlarged vacuoles
(Figure 2B). Producing or overproducing the MTM1R421Q in the
ymr1D mutant did not result in major changes in vacuolar
morphology, suggesting that this mutation strongly impairs the
enzymatic activity in vivo. Upon production (CEN) and overpro-
duction (2 m) of MTM1V49F or MTM1N180K, the percentage of
cells with small and large unilobar vacuoles increased as observed
for MTM1 (Figure 3). Thus MTM1V49F and MTM1N180K
responsible for severe and very mild forms of XLCNM respec-
tively display a phosphatase activity in vivo. Production (CEN and
2 m) of MTM1R69C resulted in similar or higher numbers of
enlarged vacuoles as compared to MTM1 (Figure 3). As for
MTM1, osmotic stress also induced fragmentation of the vacuole
in cells expressing the different MTM1 with XLCNM mutations
(Figure 2B) confirming that Fab1 kinase activity was not impaired.
To determine whether similar enlarged vacuolar phenotypes were
also observed in wild-type yeast cells (WT SEY6210) upon MTM1
expression, we analyzed the vacuolar morphology of WT cells
transformed with pVV200 or pVV204 empty plasmids or coding
for MTM1 or the different MTM1 mutants (Figure S2). The
expression of the MTM1, MTM1V49F, MTM1R69C and
MTM1N180K constructs induced an increase in the vacuolar size
in both WT and ymr1D mutant cells, showing that this phenotype
was not specific for the latter yeast mutant cells. Taken together,
our data show that the vacuolar phenotypes induced by the
different MTM1 mutants are not reflecting the severity of
XLCNM phenotypes.
The enlarged vacuolar phenotypes observed upon production of
various MTM1 proteins in yeast cells suggest that these human
phosphatases have access to their membranous PPIn substrates.
To determine their intracellular distribution, protein extracts from
ymr1D cells producing the different MTM1 proteins were
subjected to subcellular fractionation to separate the membrane
fractions P13 and P100 from the cytosolic fraction S100 (Figure
S3). MTM1 was found mainly in P13 and P100 fractions and a
similar fractionation was observed for the different MTM1
mutants. This membrane association of MTM1, despite the
absence of a transmembrane domain or a lipid anchor, suggests
that MTM1 interacts with lipids or proteins independently of its
phosphatase activity since MTM1C375S was also membrane-
associated. These results show that the different vacuolar
phenotypes observed upon production of the different MTM1
proteins are not due to differences in their subcellular distribution.
Some MTM1 disease mutants display phosphatase
activity
The vacuolar phenotypes suggest that MTM1, MTM1V49F,
MTM1R69C or MTM1N180K dephosphorylate PtdIns3P and
PtdIns(3,5)P2 in yeast cells. To assess their phosphatase activity
in vivo we determined the intracellular levels of PtdIns3P and
PtdIns5P in ymr1D cells producing the different MTM1 constructs.
Cells were labeled with 32P, lipids extracted and separated by thin-
layer chromatography (TLC) and spots corresponding to phos-
phatidylinositol-monophosphates (PtdInsP) and phosphatidylinosi-
tol-bisphosphates (PtdInsP2) were isolated, deacylated and resolved
by anion-exchange HPLC chromatography. Four different PPIn
are identified in yeast S. cerevisiae: PtdIns3P, PtdIns4P,
PtdIns(3,5)P2 and PtdIns(4,5)P2. The relative abundance of
[PtdIns3P, PtdIns4P, PtdIns(3,5)P2, PtdIns(4,5)P2] is 40:40:7:13
in wild-type SEY6210 strain whereas in fab1D mutant strain this
ratio changes to 74:21:0:5 [25]. It was previously shown that in
ymr1D cells PtdIns3P levels are 2-fold higher than in wild-type cells
and represent 82% of the total PtdInsP species [12]. To compare
the phosphatase activity of the different MTM1 constructs, we
calculated the percentage of PtdIns3P over total PtdInsP for the
different strains (Figure 4A). This showed that MTM1R421Q
mutant affecting a residue in the catalytic pocket displayed a poor
phosphatase activity, as PtdIns3P levels were comparable to those
Figure 1. Human myotubularin expression in yeast S. cerevisiae.
(A) Representation of the MTM1 protein with its domains, the position
of the mutations analyzed and the severity of the resulting myopathy
phenotype. MTM1 displays different domains, PH-GRAM (pleckstrin
homology-glucosyltransferase, Rab-like GTPase activator and myotubu-
larin), RID (Rac-induced recruitment domain), catalytic phosphatase
domain and SID (SET-protein interaction domain). (B) Anti-MTM1
Western-blot on yeast protein extracts. The MTM1 gene was placed
under the control of the tetracycline-repressible tetO promoter in the
low copy number centromeric plasmid (CEN, pVV204, 1 to 3 copies per
cell). In the high copy number 2 m plasmid (2 m, pVV200, 20 to 50 copies
per cell), the MTM1 gene was under the control of the strong yeast
PGK1 promoter. These different plasmids were transformed into the
ymr1D yeast mutant. Protein extracts of ymr1D cells transformed with
pVV204 (CEN) or pVV200 (2 m) empty plasmids (Control) or bearing the
different MTM1 forms were analyzed by Western-blot. MTM1 produc-
tion was detected with the mouse monoclonal 1G6 anti-MTM1
antibody. The different human MTM1 proteins were produced at the
expected molecular weight (70 kDa) as compared to the ymr1D cells
transformed with empty control plasmids that displayed no signal.
Protein loading was evaluated by immunodetection of the yeast
endogenous 3-phosphoglycerate kinase Pgk1 protein.
doi:10.1371/journal.pgen.1002965.g001
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Figure 2. Yeast vacuolar phenotype analysis upon MTM1 expression. The wild-type and fab1D cells were used as controls. The different
yeast cells transformed or not with pVV200 (2 m, overexpression) plasmids bearing or not wild-type or mutants MTM1 were grown to exponential
phase in selective SC-trp medium and the vacuoles were stained by FM4-64. Cell were labeled with FM4-64 for 15 min at 25uC in YPD and washed in
once in SC-trp. Cells were then observed in selective medium by fluorescence microscopy with DIC (Nomarski) and TRITC (FM4-64) filters. Osmotic
shock was induced by addition of NaCl (final concentration 0.9 M) to FM4-64 stained cultures, and cells were observed after 10 min incubation. (A)
Wild-type, fab1D and ymr1D yeast cells transformed with pVV200 empty plasmid or bearing wild-type MTM1 or the phosphatase-dead MTM1C375S
Phosphatase-Independent Roles of Myotubularin
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of the phosphatase-dead MTM1C375S control. In contrast, the
three other XLCNM patient mutants MTM1V49F, MTM1R69C
and MTM1N180K showed PtdIns3P phosphatase activity compa-
rable to the wild-type MTM1, as they displayed a strong decrease
in the PtdIns3P levels which represented only 45–50% of total
PtdInsP (Figure 4A). These results were confirmed by in vitro
phosphatase assays [28] done on MTM1, MTM1C375S,
MTM1V49F, MTM1R69C and MTM1N180K proteins immuno-
isolated from yeast ymr1D cells (Figure S4).
Among the different PPIn detected in yeast cells, the
PtdIns(3,5)P2 is the least abundant and represents about 0.1% of
the total inositol phospholipids [18]. Indeed, HPLC chromato-
grams of PtdInsP2 showed that under our experimental conditions
PtdIns(3,5)P2 was barely detectable in normal conditions for the
different strains (not shown). PtdIns(3,5)P2 intracellular levels can
be increased by osmotic shock [26]. To avoid any osmotic stress
treatment of the cells and to detect PtdIns(3,5)P2 dephosphoryla-
tion by MTM1 under normal conditions, we quantified the
resulting product PtdIns5P by a sensitive mass assay [28,29]. Thus
ymr1D yeast cells producing MTM1, MTM1C375S, MTM1V49F,
MTM1R69C, MTM1N180K and MTM1R421Q were grown to
exponential phase, lipids were extracted and separated by TLC,
and spots corresponding to PtdInsP were extracted and submitted
to an in vitro kinase assay to detect PtdIns5P. The ymr1D cells
expressing MTM1C375S or the empty plasmid showed a basal level
of PtdIns5P, whereas in the presence of active MTM1 there was a
strong increase in PtdIns5P (Figure 4B). Comparison of PtdIns5P
levels showed that MTM1R421Q can be considered as an inactive
phosphatase, as it displayed similar levels to MTM1C375S
(Figure 4B). The three other XLCNM patient mutants
MTM1V49F, MTM1R69C and MTM1N180K displayed a
PtdIns(3,5)P2 phosphatase activity since significant quantities of
PtdIns5P were detected (Figure 4B). Based on the p-values
(Figure 4B), the PtdIns5P production by the MTM1R69C mutant
is not significantly different than the one detected for MTM1.
These results were further confirmed by in vitro phosphatase assays
showing proper dephosphorylation of PtdIns(3,5)P2 by MTM1,
MTM1V49F, MTM1R69C and MTM1N180K produced in yeast
ymr1D cells, whereas in the same conditions the MTM1C375S and
MTM1R421Q were less active (Figure S4).
These results show that MTM1 mutants responsible for
myopathy are either active or inactive phosphatases. Indeed, the
MTM1V49F mutant is associated to severe forms of the disease and
displays phosphatase activity, even so its activity is reduced
compared to the wild type phosphatase. The second mutant in the
PH-GRAM domain of MTM1, MTM1R69C shows similar
phosphatase activity as the wild-type MTM1 and is associated to
mild or severe phenotype. In conclusion, not all MTM1 mutants
responsible for myopathy lack the phosphatase activity.
Exogenous expression of myotubularin ameliorates the
histological phenotype of Mtm1 KO muscle independent
of its enzymatic activity
As results in yeast suggested that some XLCNM patient
mutants retain the phosphatase activity, we aimed to investigate
the role of the phosphatase activity on the development of the
XLCNM phenotype in vivo. We tested the ability of the
MTM1C375S phosphatase-dead mutant to correct the XLCNM-
like muscle phenotype of Mtm1 knockout (KO) mice compared to
wild-type MTM1 using Adeno-associated virus (AAV) gene
transfer. We used the constitutive Mtm1 KO mouse that develops
a homogeneous XLCNM in the 129PAS background [30]. These
mutant animals show a progressive muscle weakness starting
clinically at 3 weeks of age and leading to death by 7 to 9 weeks,
probably from respiratory failure. They display most phenotypes
mutant. Inset shows an increased magnification of a representative cell to illustrate the vacuolar phenotype upon osmotic shock. (B) ymr1D cells
transformed with pVV200 plasmid bearing the different MTM1 mutants responsible for XLCNM myopathy.
doi:10.1371/journal.pgen.1002965.g002
Figure 3. Vacuolar morphologies quantification in yeast cells
producing MTM1. The ymr1D cells expressing either wild-type MTM1
or the different MTM1 mutants from either pVV200 (2 m, overexpres-
sion) or pVV204 (CEN, expression) plasmid were analyzed. For each
strain, 300 to 600 cells were observed by microscopy (DIC and FM4-64)
and sorted into one of the three categories: unilobar large or giant (in
white), small one or two lobes (in grey) and more than two lobes or
fragmented (in black) vacuoles. The main vacuolar phenotype of the
non-transformed ymr1D mutant cells is fragmented vacuoles with more
than two lobes. Histograms are the mean of three independent
experiments and show the proportion of each category in the different
transformed yeast cells.
doi:10.1371/journal.pgen.1002965.g003
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observed in patients as a decrease in muscle mass, muscle fiber
hypotrophy, nuclei and mitochondria positioning defects, desmin
aggregation, and alteration in T-tubule structure. At 6 weeks old,
Mtm1 KO mice injected with empty AAV vector show a 38%
decrease in the Tibialis anterior (TA) muscle weight compared to
wild-type mice injected with empty AAV (Figure 5C). Mtm1 KO
Figure 4. Determination of different phosphoinositides (PPIn) levels upon expression of MTM1 wild-type or mutant proteins. (A)
Quantification of PtdIns3P cellular levels of ymr1D cells expressing wild-type MTM1 or the different mutants from pVV204 (CEN). Strains were grown
to early log phase in selective medium, labeled with 32P and lipids were extracted and prepared for HPLC analysis. Based on HPLC chromatograms the
peak area corresponding to each PPIn species was determined and results were expressed as the percentage of 32P-PtdIns3P compared to the total
labeled 32P-PtdInsP. Results are represented as the mean of at least two independent experiments shown with standard deviations. (B) Quantitative
analysis of PtdIns5P produced in ymr1D cells expressing wild-type or mutants MTM1. Strains were grown to log phase in selective medium, lipid were
extracted, separated by TLC and spots corresponding to mono-phosphorylated PPIn were scrapped off and subjected to phosphorylation by
PtdIns5P 4-kinase type IIa in presence of [c-32P]-ATP. This kinase is specific for PtdIns5P and produces PtdIns(4,5)P2. The
32P-labeled PtdIns(4,5)P2
generated from this in vitro kinase reaction was further analyzed by TLC and radioactivity was quantified in a scintillation counter. The total amount of
PtdIns5P (pmol) in each sample was determined by comparison with a calibration curve made from diC16-PtdIns5P and normalized to the number of
yeast cells. Graph represents PtdIns5P as a percentage of production compared to the wild type myotubularin MTM1 (n= 3 to 4 experiments). The p-
value for each construct was evaluated versus the wild type MTM1 and is indicated at the top of the graph. A p-value of less than 0.05 indicates that
the difference in the two PtdIns5P percentages is statistically significant. The p-value was 0.0021 for MTM1V49F versus MTM1C375S and 0.0036 for
MTM1V49F versus MTM1R421Q.
doi:10.1371/journal.pgen.1002965.g004
Phosphatase-Independent Roles of Myotubularin
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TA muscles displayed smaller and rounder myofibers with
increased proportion of internal nuclei compared to wild-type
mice (Figure 5B and 5D). In addition, Mtm1 KO muscles had an
abnormal oxidative staining with higher intensities in the
subsarcolemmal region and in the center of fibers, reminiscent
of an accumulation of mitochondria at these regions (Figure 5B).
TA muscles of 2–3 weeks old Mtm1 KO mice were injected with
either AAV2/1-Mtm1-WT (AAV-Mtm1-WT) or AAV2/1-Mtm1-
C375S (AAV-Mtm1-CS), where the C375S mutation abolishes the
phosphatase enzymatic activity towards PPIn substrates (Figure 4).
The contralateral muscle was injected with AAV2/1-Empty
(AAV) as an internal control. The effect of AAV-mediated
Mtm1-WT or Mtm1-CS expression was analyzed 4 weeks after
injection. The level of ectopic Mtm1-WT and Mtm1-CS expression
was analyzed by western blot in injected muscles. In both injected
muscles the level of the protein was reestablished and similar to the
levels of the endogenous protein in WT muscle (Figure 5A).
We confirmed that exogenous expression of Mtm1-WT in TA
muscle corrects the XLCNM-like phenotype in the constitutive
129PAS Mtm1 KO mice, as previously shown in muscle-specific
KO mice on a B6 background [31], showing that the MTM1
protein is acting primarily in skeletal muscle and not in other
tissues as only muscle was injected. The Mtm1 KO model displays
a severe muscle atrophy (Figure 5 and [4,30]). Muscles injected
with AAV-Mtm1-CS showed a significant increase of the weight
compared to Mtm1 KO muscle injected with AAV (0,13%60,03
for AAV-Mtm1-CS compared to 0,08%60,02 for AAV alone),
reaching similar levels to Mtm1 KO injected with Mtm1-WT
(Figure 5C). Next we investigated if the increase in weight
correlates with an improvement at the histological level. Hema-
toxylin and eosin (HE) staining revealed similar improvement of
the histological aspects of Mtm1 KO muscles injected with either
AAV-Mtm1-WT or AAV-Mtm1-CS (Figure 5B). Quantitative
analysis of the distribution of myofiber areas showed a clear
increase in fiber size for both AAV-Mtm1-WT and AAV-Mtm1-CS
treated muscles compared to Mtm1 KO muscles (Figure 5E). None
of the constructs restored fiber area and the muscle weight to the
level of wild-type mice 4 weeks after infection and it was not
possible to test if longer infection would increase the correction of
these features under our experimental conditions as mice were
dying around the age of analysis. Fiber area distribution is different
comparing AAV-Mtm1-WT and AAV-Mtm1-CS; AAV-Mtm1-CS
leads to a higher increase in the number of fibers with an area in
the range of 200 to 3200 mm2, compared to fibers with an area
superior to 3200 mm2 with AAV-Mtm1-WT. Our data show that
both AAV-Mtm1-WT and AAV-Mtm1-CS partially but signifi-
cantly improved muscle atrophy and fiber hypotrophy of theMtm1
KO mice.
Furthermore Mtm1 KO muscle fibers are also characterized by
a progressive disorganization in the distribution of mitochondria.
Thus, we evaluated the localization of these organelles by
succinate dehydrogenase staining (SDH) that labels the oxidative
activity. The SDH staining of muscle sections (Figure 5B) revealed
that the abnormal central concentration of oxidative activity was
improved with both AAV-Mtm1-WT and AAV-Mtm1-CS. In
addition, abnormal internalization of nuclei represents another
hallmark of the XLCNM pathology. We thus counted the number
of fibers with internal nuclei (not in contact with the sarcolemma)
in wild-type and Mtm1 KO muscles injected with AAV versus
Mtm1 KO muscles treated with AAV-Mtm1-WT or AAV-Mtm1-
CS (Figure 5D). We observed a strong and similar reduction of the
percentage of internal nuclei in AAV-Mtm1-WT and AAV-Mtm1-
CS treated muscles compared to Mtm1 KO muscles
(21,15%68,23 for AAV-Mtm1-CS; 15,68%60,62 for AAV-
Mtm1-WT compared to 46,67%68,18 for Mtm1 KO and
2,28%62,11 for wild-type mice).
The phosphatase-dead myotubularin improves muscle
strength
To determine whether the significant improvement of the
histological features was associated to improved muscle perfor-
mance, we measured the in situ force of the muscle. The isolated
muscle was stimulated by the sciatic nerve, and the maximal force
produced was recorded and normalized to muscle weight
(Figure 6). The specific maximal force of untreated TA muscles
of 6 week-old Mtm1 KO mice was lower by 81% compared to
wild-type muscle. The muscles transduced with AAV-Mtm1-CS
and AAV-Mtm1-WT exhibit an increase of the specific maximal
force compared toMtm1 KO (0,44 mN/mg60,23 for AAV-Mtm1-
CS; 0,66 mN/mg60,17 for AAV-Mtm1-WT compared to
0,06 mN/mg60,04 for Mtm1 KO and 1,31 mN/mg60,21 for
wild-type mice) (Figure 6). Altogether, our results show that the
MTM1C375S phosphatase-dead mutant improves most XLCNM-
like histological and the specific muscle force of the Mtm1 KO
model at a level comparable to that of the wild-type MTM1
protein.
MTM1C375S phosphatase-dead mutant restores the
abnormal desmin organization in Mtm1-deficient muscle
To further decipher the molecular basis for these phosphatase-
independent improvements we analyzed the localization of
desmin, a muscular MTM1 protein interactor. Indeed, it was
recently shown that MTM1 binds specifically desmin and
regulates the filament assembly and organization [32]. Desmin is
the major component of intermediate filaments (IFs) cytoskeleton
of muscle, which plays a central role in the integration of structure
and function of striated muscle by linking the contractile apparatus
to the sarcolemmal cytoskeleton as well as to several cytoplamic
organelles and the nucleus. Desmin is found mainly in the Z-disk
in a normal skeletal muscle. In the muscle biopsies from XLCNM
patients, desmin localization is altered. The Mtm1 KO mice
muscles present an accumulation of aggregates that disrupt the
continuity and organization of the desmin network (Figure 7A).
We could previously show that ectopic expression of MTM1-WT
in the Mtm1 KO muscle restores the normal organization of the
desmin network [32]. We examined the muscle injected with the
MTM1C375S phosphatase-dead mutant. The muscle transduced
with AAV-Mtm1-CS exhibited a clear improvement of the desmin
localization compared to the desmin aggregates observed in the
Mtm1 KO muscle injected with the empty virus (Figure 7A).
Furthermore, the mislocalization of desmin in Mtm1 KO
corresponds also to a shift in desmin equilibrium from the soluble
to the insoluble fraction, indicating a defect in the desmin assembly
process (Figure 7B). We observed a significant and similar increase
in the desmin solubility in AAV-Mtm1-WT and AAV-Mtm1-CS
treated muscles compared to Mtm1 KO muscles (Figure 7B). To
confirm that AAV-Mtm1-WT and AAV-Mtm1-CS displayed
similar efficiency regarding the correction of desmin solubility
we analyzed the level of MTM1 expression in the same samples
(Figure 7C). The MTM1 expression was similar in both type of
muscles suggesting that phosphatase-dead mutant MTM1C375S
improves the desmin organization as efficiently as MTM1-WT.
Moreover, we analyzed the distribution of MTM1-WT and
MTM1-C375S in the membrane fraction of skeletal muscle using
a microsomal preparation from Mtm1 KO muscles injected with
AAV-Mtm1-WT and AAV-Mtm1-CS and from wild-type muscle.
Microsomal fractions were analyzed using protein markers for the
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membrane fraction (a-sarcoglycan and SERCA1), for the cyto-
plasmic (b-tubulin) and for the nuclear fractions (the TATA-box
binding protein (TBP)). The MTM1-WT and MTM1-C375S
proteins ectopically expressed in the Mtm1-KO muscle were
similarly distributed in the microsomal fractions (Figure 7F). These
results suggest that MTM1-WT and MTM1-C375S localize
similarly in the membrane fraction in skeletal muscle.
Altogether, our results show that the phosphatase activity of
MTM1 is not required for normal desmin localization in muscle
fibers, and suggest that maintenance of the desmin network is a
phosphatase-independent function of MTM1 that is important in
XLCNM.
Improvement of the ultrastructural organization of triads
in Mtm1 KO muscles
To determine whether the substantial amelioration of the
histological features was correlated to the improvement of the
structural organization of the triads, we analyzed the muscles by
electron microscopy. Indeed, previous studies have shown that the
muscles lacking myotubularin as well as XLCNM muscle biopsies
Figure 5. Amelioration of muscle atrophy and fiber hypotrophy in a murine model of centronuclear myopathy by AAV–mediated
expression of two phosphatase-inactive myotubularin mutants MTM1C375S and MTM1S376N. (A) Skeletal muscle protein lysates 4 weeks
post-injection were immunoblotted for MTM1 and GAPDH levels in WT and Mtm1 KO mice injected with empty AAV, Mtm1 KO injected with AAV-
Mtm1-WT, AAV-Mtm1-CS and AAV- Mtm1-SN. (B) Hematoxylin and eosin (HE, left panels, magnification6400) and succinate dehydrogenase (SDH,
right panels,6400) staining of TA cross-sections from WT mice injected with empty AAV, Mtm1 KO injected with empty AAV, AAV-Mtm1-WT, AAV-
Mtm1-CS and AAV-Mtm1-SN mice 4 weeks PI. Mtm1 KO muscle sections show the presence of very small myofibers and internalized nuclei.
Mitochondrial oxidative staining is abnormally accumulated at the centre of fibers. Note the recovery of oxidative reactivity pattern in myotubularin-
expressing Mtm1 KO muscles. Scale bar: 50 mm. (C) Graph represents TA weight as a percentage of total body weight (n = 6 mice). P values,0.01 for
WT injected with AAV versus KO injected with AAV, AAV-Mtm1-WT, AAV-Mtm1-CS and AAV-Mtm1-SN. P values,0.001 for KO injected with AAV versus
AAV-Mtm1-WT, AAV-Mtm1-CS and AAV-Mtm1-SN. (D) Percentage of muscle fibers with internalized nuclei after AAV, AAV-Mtm1-WT, AAV-Mtm1-CS
and AAV-Mtm1-SN injection of Mtm1 KO mice. Nuclei were considered as internalized if not in contact with the sarcolemma. The number of fibers
with internal nuclei is increased in Mtm1 KO tibialis anterior (TA) muscle and significantly and equally reduced after injection with AAV-Mtm1-WT or
AAV-Mtm1-CS or AAV-Mtm1-SN (n = 550). P values,0.009 for WT injected with AAV versus KO injected with AAV, AAV-Mtm1-WT, AAV-Mtm1-CS and
AAV-Mtm1-SN. P values p,0.0009 for KO injected with AAV versus AAV-Mtm1-WT, AAV-Mtm1-CS and AAV-Mtm1-SN. (E) Transverse muscle sections
were analyzed for fiber area. Fiber size is grouped into 200 mm2 intervals, and represented as the percentage of total fibers in each group (n = 1,000
for 15 mice for AAV-Mtm1-WT, AAV-Mtm1-CS and 6 mice for AAV-Mtm1-SN group).
doi:10.1371/journal.pgen.1002965.g005
Phosphatase-Independent Roles of Myotubularin
PLOS Genetics | www.plosgenetics.org 8 October 2012 | Volume 8 | Issue 10 | e1002965
present abnormal organization of triads [30,33,34]. The electron
micrographs obtained from the wild-type, Mtm1 KO and Mtm1
KO injected with AAV-Mtm1-WT and AAV-Mtm1-CS muscles
were analyzed. The wild-type muscle showed proper organization
of the fibers and sarcomere arrangement, and the typical triad
structure. In contrast, the micrographs from Mtm1 KO muscle
exhibited sarcomere disorganization and a decrease in the number
of well-positioned triads (Figure 8A and 8B). Interestingly, the
Mtm1-KO muscle injected with AAV-Mtm1-WT showed a clear
improvement in the general organization of the sarcomere and the
presence of the well–formed triads (Figure 8A–8C). An improve-
ment was also observed in the Mtm1 KO muscle injected with the
AAV-Mtm1-CS. The ratio of triads per sarcomere in Mtm1 KO
muscles of 6 weeks-old mice was decreased by 83% compared to
wild-type muscle. Muscles transduced with AAV-Mtm1-WT and
AAV-Mtm1-CS presented a significant increase in this ratio
(0,960,18 for AAV-Mtm1-CS; 1,0460,24 for AAV-Mtm1-WT
compared to 0,2360,21 for Mtm1 KO and 1,260,3 for wild-type
mice) (Figure 8B). In addition, the shape of the triad was analyzed
in the wild-type and in the Mtm1-KO muscle transduced with
AAV-Mtm1-WT and AAV-Mtm1-CS. The Mtm1 KO was not
considered for this analysis, as recognizable triads were nearly
absent in this muscle. The muscle transduced with the phospha-
tase-dead mutant exhibited recognizable triads with a more dilated
shape than the muscle transduced with the AAV-Mtm1-WT and
wild-type muscle (Figure 8C).
Altogether, our results show that the MTM1C375S phosphatase-
dead mutant improves the general organization of the muscle
fibers and restores the presence and number of the triads in the
Mtm1 KO model at a level comparable to the wild-type MTM1
protein. However the muscle transduced with AAV-Mtm1-CS
exhibited only a partial correction of the shape of the triads
compared to the AAV-Mtm1-WT, suggesting a potential role of
the phosphatase activity in the shape of the triad.
The phenotypic improvement does not correlate with
normalization of PtdIns3P levels
To determine whether the MTM1 phosphatase activity
contributed to the improvement of the XLCNM phenotypes, we
measured the level of PtdIns3P in the different muscles. For these
measurements, we extracted total lipids from the tibialis anterior of
wild-type, Mtm1-KO and Mtm1-KO muscles injected with AAV-
Mtm1-WT or AAV-Mtm1-CS. We used a novel sensitive mass
assay for measuring PtdIns3P from total muscle lipid extracts
without metabolic labeling [35]. The level of PtdIns3P in the
sample was quantified and normalized to total phospholipids, the
resulting pmol of PtdIns3P/mmol of phospholipids data were
expressed as fold increase compared to the wild-type muscle
transduced with AAV (Figure 9). The lipid extracts from Mtm1
KO mice exhibited a higher level of PtdIns3P compared to wild-
type (2.19 fold increase for Mtm1 KO muscle). These data support
the conclusion that PtdIns3P is a physiological substrate of MTM1
in mammalian muscle and that the disease is paralleled by an
alteration of PPIn metabolism in the Mtm1 KO model. The lipid
extracts from the muscles transduced with AAV-Mtm1-WT
showed a normalization of the PtdIns3P to levels similar as the
wild-type muscle. In contrast, muscles transduced with AAV-
Mtm1-CS exhibited, as the Mtm1 KO muscles, higher levels of
Ptdns3P compared to the wild-type muscle (3.3 fold increase for
AAV-Mtm1-CS) (Figure 9). The difference in PtdIns3P levels
between the Mtm1 KO injected with empty AAV and AAV-Mtm1-
CS is not statistically significant since the p-value is 0.06. However,
there is a tendency towards increased PtdIns3P levels with AAV-
Mtm1-CS that could be caused by a substrate-trapping property of
this mutant resulting in the protection of PtdIns3P from
consumption by other enzymes. Thus, the Mtm1-C375S mutant
is catalytically inactive in vivo and might be a substrate-trapping
mutant. The results show that the correction of the phenotypes
with the MTM1C375S phosphatase-dead was not correlated to
normalization of the PtdIns3P levels in muscle.
The rescuing potential of the phosphatase-dead mutant
is very likely not due to substrate-trapping properties
The analysis of the PtdIns3P level in mice muscles did not
exclude that the MTM1C375S mutant might be a substrate-
trapping mutant. Thus, this mutant could promote the correction
of the Mtm1 KO mice phenotypes through a dominant-negative
effect by blocking the access of effectors to PtdIns3P and/or
PtdIns(3,5)P2. To address this issue, we used the MTM1
S376N
(Mtm1-SN) mutant associated to severe XLCNM [36]. The S376N
mutation located in the catalytic site abrogates the in vitro
phosphatase activity [12] and this inactive mutant was predicted
to disrupt the substrates binding based on the myotubularin
MTMR2 crystal structure [37]. Indeed, the replacement of this
serine 376 with a bulkier aminoacid removes the hydrogen bond
formed with the oxygen of the D1 phosphate of the lipid substrate
and is also predicted to produce an allosteric clash with both the
D1 phosphate of the substrate and with two aminoacids of the
catalytic pocket (Asp280 and Asp288, Figure S5). To determine its
in vivo activity, we produced this mutant in yeast ymr1D cells,
analyzed the vacuolar size and quantified the resulting PtdIns5P
product (Figure S5). The results show that the MTM1S376N
protein is produced in yeast cells, and that this MTM1S376N
mutant is catalytically inactive as judged from the vacuolar
phenotypes and the lack of dephosphorylation of PtdIns(3,5)P2 in
PtdIns5P (Figure S5). Next, we analyzed the major XLCNM-like
phenotypes in the Mtm1 KO muscle injected with AAV-Mtm1-SN
mutant (Figure 5). The Mtm1 KO muscles transduced with AAV-
Figure 6. The phosphatase-dead C375S myotubularin mutant
improves muscle force in Mtm1 KO mice. The specific maximal
force (sP0) of WT muscle injected with AAV and Mtm1 KO TA muscle
injected with AAV, AAV-Mtm1-WT and AAV-Mtm1-CS. The sP0
represents the absolute maximal force related to muscle weight (n = 6
mice, *P,0.001).
doi:10.1371/journal.pgen.1002965.g006
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Mtm1-CS showed a clear improvement of the muscle concerning
the muscle weight, fiber size, organelle and nuclei positioning and
a similar improvement was observed for the injection of AAV-
Mtm1-SN mutant (Figure 5). While not excluding that the C375SS
mutant could have some substrate-trapping properties, these
results strongly suggest that the amelioration of the XLCNM
phenotypes described for AAV-Mtm1-CS are not due to a
substrate-trap effect of the C375S mutation. As the S376N mutant
is also phosphatase-dead, this supports the conclusion that the
MTM1 phosphatase activity does not contribute to the mainte-
nance of most XLCNM phenotypes.
Discussion
In this study, we investigated the involvement of MTM1
enzymatic activity on the phenotypes of XLCNM. Using
heterologous expression of human genes in yeast, we showed
that the PPIn phosphatase activity of MTM1 was directly
linked to vacuolar homeostasis. The vacuolar phenotypes
induced by expressing different MTM1 mutants found in
patients and their measured impact on PPIn levels revealed
that not all MTM1 mutants were associated to inactive
phosphatase. In addition, using gene transfer in a murine
model of XLCNM, we were able to significantly ameliorate
most morphological phenotypes with two different phospha-
tase-inactive mutants of MTM1. Altogether, our data strongly
suggest that the main roles of MTM1 in adult muscle are
largely independent of its enzymatic activity, with the
exception of triad shape and fiber size distribution.
We report here a sensitive assay to determine human MTM1
phosphatase activity in yeast S. cerevisiae using vacuole size as a
read-out. We showed that vacuole size correlates with the levels of
intracellular PtdIns3P and PtdIns(3,5)P2 dephosphorylated by
MTM1. In yeast cells, a reverse correlation was observed between
the in vivo phosphatase activity and the MTM1 protein level.
Indeed, the enzymatically inactive MTM1R421Q and MTM1C375S
are the most produced whereas the most active MTM1R69C was
the least abundant (Figure 1B). This suggests that yeast cells
regulate the levels of human MTM1 to avoid massive deregulation
of PPIn levels. This regulation could be post-transcriptional since
the same effect was observed with two different replication origins
(2 m or CEN-ARS) combined with two different promoters, the
yeast PGK1 and the bacterial tetO promoters. Thus, an equilibrium
between intracellular protein levels and PtdIns3P and
PtdIns(3,5)P2 dephosphorylation rates may have been reached to
ensure yeast growth in the presence of human MTM1 active
Figure 7. The phosphatase-dead C375S myotubularin mutant injection in Mtm1-KO muscle restores normal desmin expression and
localization. (A) Ectopic expression of MTM1 transgene in Mtm1-KO muscle restored normal desmin localization in muscle. Arrowheads indicate
aggregates of desmin in Mtm1-KO muscle injected with AAV. Scale bars: 10 mm. (B) The phosphatase-dead C375S myotubularin mutant expression in
Mtm1-KO muscle restored normal desmin expression level in soluble and insoluble fraction. (C) Skeletal muscle protein lysates 4 weeks post-injection
were immunoblotted for MTM1. (D) Quantification of relative desmin expression level in soluble compared to insoluble fraction. Data correlated from
2 independent experiments (n = 3 mice per group). *P#0.05. (E) Quantification of relative expression of MTM1 in WT and Mtm1 KO mice injected with
empty AAV, Mtm1 KO injected with AAV-Mtm1-WT and AAV-Mtm1-CS. (F) Microsome fractions from Mtm1 KO muscles injected with AAV-Mtm1-WT
and AAV-Mtm1-CS and from wild-type muscles were prepared and immunoblotted for MTM1 to compare localization of MTM1-WT and MTM1-C375S
in the membrane fraction of the muscle. Microsome fractions were immunoblotted with antibodies detecting membrane proteins (SERCA1 and
Sarcoglycan), cytoplasmic protein (b-tubulin) and nuclear protein (TATA-box binding protein (TBP)).
doi:10.1371/journal.pgen.1002965.g007
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forms. This is further supported by the fact that despite being
massively produced in yeast, enzymatically active MTM1 did not
drastically deplete intracellular PtdIns3P but restored similar
PtdIns3P levels to the SEY6210 WT strain. It may also reflect a
specificity of MTM1 towards distinct intracellular subpools of
PtdIns3P.
Using different approaches in two eukaryotic models, the yeast
S. cerevisiae ymr1D and the Mtm1 KO mouse, our results indicate
that the XLCNM disease is not solely linked to a defect in MTM1
phosphatase activity. In yeast cells, several XLCNM patient
mutants responsible for severe forms of the disease displayed a
phosphatase activity comparable to wild-type MTM1. In this
model, the MTM1 phosphatase activity was linked to vacuolar
homeostasis, in accordance with the known function of PtdIns3P
and PtdIns(3,5)P2 in yeast cells [18]. In the Mtm1 KO mice AAV
gene transfer of wild-type MTM1 or phosphatase-inactive
MTM1C375S and MTM1S376N mutants significantly improved
the XLCNM phenotypes. Comparison of AAV-Mtm1-WT and
AAV-Mtm1-CS injected Mtm1 KO mice muscles revealed that
ectopic expression of MTM1C375S phosphatase-dead mutant
corrected similarly as MTM1 wild-type: the muscle weight, nuclei
positioning, oxidative staining and fiber shape (HE staining),
desmin localization and solubility, sarcomere organization, the
presence of well-oriented triads at the sarcomere and the specific
maximal force, whereas the distribution of the fiber size and the
triads shape were only partially ameliorated (Figure 10). Whether
the complete correction of these phenotypes requires longer time
of expression or the phosphatase activity of MTM1 remains an
open question. Thus, apart from PtdIns3P levels, which are mainly
dependent on the phosphatase activity, only fiber size distribution
and triads shape appear both phosphatase-dependent and
phosphate-independent functions of MTM1. Interestingly, since
mice were injected with MTM1C375S or MTM1S376N at 3 weeks
when animals start to present some pathological signs, it supports
that these dead phosphatases did not only improve but were also
able to revert the progression of the disease. Thus, even though the
phosphatase activity of MTM1 is very important for its cellular
function likely by impacting on vesicular trafficking, the loss of this
activity is not responsible for the maintenance of most muscle
phenotypes observed in the disease. This strongly suggests that
defects in PPIn metabolism and vacuolar homeostasis are not the
main cause in the maintenance of XLCNM phenotypes. However,
we do not exclude that defect in the regulation of triad shape may
affect muscle function at later stages, even so we did not observe
significant differences in muscular specific maximal force after 4
weeks of transduction. Based on previous studies and on our
results, we favor the hypothesis that the MTM1 phosphatase
activity is crucial for the onset of the disease but less important for
its maintenance in later stages of the myopathy. In this study only
the PtdIns3P levels could be measured in the muscle, thus we
Figure 8. Improvement of triad abnormalities present in Mtm1-deficient muscles with AAV-Mtm1-WT and AAV-Mtm1-CS. (A)
Sarcomere and triad (arrowheads) organization in wild-type muscle, Mtm1 KO muscle, Mtm1 KO muscles injected with AAV-Mtm1-WT and AAV-Mtm1-
CS at 2 different magnifications. Muscles from Mtm1 KO demonstrate a severe disorganization of the muscle fiber with lack of recognizable triads
within the sarcomere structure. (B) Quantification of the presence of triads in the muscle fibers. The graph represents the ratio between the number
of triads observed in each longitudinal section divided by the total number of sarcomeres present in the section. (C) Triads shape in wild-type muscle,
and Mtm1 KO muscles injected with AAV-Mtm1-WT and AAV-Mtm1-CS.
doi:10.1371/journal.pgen.1002965.g008
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cannot exclude that there might be a correlation with restored
PtdIns(3,5)P2, although the MTM1
C375S mutant was shown to lack
enzymatic activity against both PtdIns3P and PtdIns(3,5)P2 [28].
Moreover, Kiger and colleagues reported that down regulation of
PI3K class II (Pi3K68D) in drosophila could rescue viability and
several defects observed in mutant of mtm, the fly orthologue for
MTM1, MTMR1 and MTMR2 [17,38]. It is possible that in fly
the role of myotubularins are more tightly linked to the
phosphatase activity than in mammals where the diversification
of myotubularins may have developed some phosphatase-inde-
pendent and tissue-specific functions.
Mutations responsible for XLCNM are found all along the
MTM1 protein [3,6]. For most of them, including missense
mutations, the MTM1 protein level was strongly decreased or not
detectable in fibroblasts, lymphoblasts or myoblasts from patients,
suggesting that XLCNM results in most cases from the absence or
instability of MTM1 [8]. Recent results show that Mtm1 p.R69C
mice model is associated to mild CNM phenotypes with
undetectable MTM1 protein levels, however the presence of
residual protein that might account for the milder phenotype
compared to the Mtm1 KO mice cannot be ruled out [39]. One
exception was the MTM1S376N mutant associated to normal
protein level in lymphoblast and leading to severe XLCNM [8,9].
The MTM1S376N mutant is phosphatase inactive in vitro [12] and
in vivo (Figure S5). However, the level of this MTM1 mutant was
not investigated in patients’ muscle, as it requires a muscle biopsy
from a patient deceased a long time ago in the neonatal period,
and thus it is possible that this mutation leads to the instability of
the protein in muscle. Moreover, Pierson et al. recently showed
that the mutation predicted to lead to the R69C aminoacid change
was in fact promoting a splicing defect and loss of the protein in
the skeletal muscle of the R69C knock-in mice [39], suggesting
that other missense mutations might impact on splicing in the
diseased tissue. As exogenous expression of this MTM1S376N
mutant and of the phosphatase-dead MTM1C375S improves
muscle atrophy, fiber hypotrophy and organelles positioning
defects, we conclude that these pathways are not mainly linked
to the phosphatase activity but to other functions of MTM1. Based
on these new findings, we rather propose that the MTM1
myotubularin protein might be a key effector involved in complex
protein-protein interactions required for proper muscular func-
tions. Indeed, MTM1 does not display a skeletal muscle-specific
expression [40], whereas the XLCNM disease is mostly restricted
to skeletal muscle. This would suggest that MTM1 interacts with
muscle specific proteins and is required for their proper
localization/function. Among these, the muscle-specific interme-
diate filament desmin involved in organelle positioning is a good
candidate. MTM1 is required for proper desmin localization and
assembly and some XLCNM-causing mutations disrupt the
MTM1-desmin interaction [32]. Furthermore the MTM1C375S
phosphatase-dead mutant restores the abnormal desmin organi-
zation in MTM1-deficient muscle, suggesting that the phosphatase
activity of MTM1 is not required for normal desmin organization
and assembly in muscle fibers. Thus, the maintenance of desmin
organization and IFs network is a phosphatase-independent
function of MTM1 that is important for maintenance of the
muscle structure and function.
Our work also shows that a disease due to mutation(s) affecting
an enzyme is not always associated with loss of the corresponding
enzymatic activity. Such dual function of PPIn metabolizing
enzymes has been described for class I PI3K. Knock-out mice
lacking PI3K protein expression show different phenotypes than
knock-in mice expressing a kinase-dead mutant [41,42]. More-
over, manipulation of myotubularins or other PPIn regulatory
proteins by knock-down, overexpression or specific intracellular
targeting is being widely used to decipher the roles of these lipids
[43]. Our results call for cautiousness when interpreting the
observed effects as they may result from a function unrelated to
their enzymatic activity.
In conclusion, our data unravel an important and novel aspect
of XLCNM as we provide evidences for a scaffolding activity of
MTM1 for muscle specific proteins, such as desmin, which
appears more important than its phosphatase activity in the
maintenance of the XLCNM pathology. Our findings have
important implications in the design of therapeutic approaches
aiming to manipulate the phosphoinositide level in the different
diseases linked to myotubularin homologues. Whether the MTM1
phosphatase activity is also dispensable for the development of the
disease and the exact link between PPIn modulation and muscle
function remains to be established.
Materials and Methods
Ethics statement
Animals were housed in a temperature-controlled room (19–
22uC) with a 12:12-h light/dark cycle. Mice were humanely killed
by CO2 inhalation followed by cervical dislocation, according to
national and European legislations on animal experimentation.
Plasmids, yeast strains, and media
The human MTM1 ORF was cloned into pENTRTM1A
plasmid (Invitrogen) to generate an entry clone. Gateway system
(Invitrogen) was used to clone the different MTM1 constructs into
the yeast expression vectors pVV200 and pVV204 or into a
pAAV-MCS vector.
S. cerevisiae fab1D (MATa ura3D0, leu2D0, his3-D1, met15-
D0, fab1::kanMX4) mutant (EUROSCARF collection), ymr1D
Figure 9. MTM1-WT but not MTM1-C375S normalizes PtdIns3P
levels in the injected muscles. Lipids were extracted from wild-type,
Mtm1 KO, and Mtm1-KO injected with AAV-Mtm1-WT and AAV-Mtm1-CS
tibialis anterior muscles and PtdIns3P levels were quantified. The results
were presented as the levels of PtdIns3P to the total phospholipids. The
graphs represent the mean of two independent experiments shown
with the standard deviation. *p,0.05.
doi:10.1371/journal.pgen.1002965.g009
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(MATa ura3-52, leu2-3,112, his3-D200, trp1-D901, lys2-801,
suc2-D9 ymr1::HIS3) and WT (SEY6210 strain; MATa ura3-52,
leu2-3, 112, his3-D200, trp1-D901, lys2-801, suc2-D9) cells [21]
were grown at 30uC in rich medium (YPD): 1% yeast extract,
2% peptone, 2% glucose or synthetic drop-out medium (SC):
0.67% yeast nitrogen base without amino acids, 2% glucose and
the appropriate amino acids mixture to ensure plasmid
maintenance.
Western blot analysis
Yeast cells were lysed by glass beads using a FASTprep (MP
Biomedicals) in PBS1X, sorbitol 0.3 M, Complete Mini EDTA-
free protease inhibitor cocktail (Roche Diagnostics) and PMSF
1 mM. Lysates were cleared and analyzed by SDS-PAGE and
Western blot using mouse monoclonal 1G6 anti-MTM1 (1/
10,000) [8] and mouse monoclonal anti-PGK1 (1/400) (Invitro-
gen) antibodies. Muscles were homogenized in 50 mM Tris, 10%
glycerol, 1 mM EDTA, 50 mM KCl, 10 mM beta-glycerophos-
phate, 10 mM NaF, 1 mM Na3VO4, 0.1% SDS, 2% Triton X-
100 and protease inhibitors (Roche Diagnostics) using a Polytron
homogenizer (Kinematica Inc.). Mouse anti-glyceraldehyde-3-
phosphate dehydrogenase (Chemicon) and rabbit anti-MTM1
antibody (R2868) were used for detection.
Yeast vacuolar staining
FM4-64 (Invitrogen) staining was performed as previously
described [44]. Labeled yeast cells were observed by fluorescence
microscopy (Axiovert200, Zeiss) in SC-trp medium. Cells were
counted and classified into different categories: more than two
lobes, small one or two lobes and unilobar large or giant vacuoles.
Yeast phosphoinositide analysis
Labeling and lipid extraction procedures were done as
previously described [45]. ymr1D cells expressing MTM1 were
grown for 16 h in presence of 40 mCi/ml H3
32PO4 (Perkin
Elmer) before lysis by TCA. Lipids were extracted with 95%
EtOH:diethyl ether:pyridine at 15:5:1 v/v. Samples were
analyzed by TLC and labeled spots were identified by
autoradiography and PPIn standards. Labeled PtdInsP as well
as PtdInsP2 were scraped off the plates, collected and deacylated
before being analyzed by high-performance liquid chromatogra-
phy (HPLC) Whatman PartiSphere 5 SAX (4.66125 mm) as
previously described [46].
PtdIns5P and PtdIns3P mass assay from yeast and muscle
extracts
ymr1D cells producing the different MTM1 were grown to
exponential phase, lipids extraction and TLC separation were
performed as described above. Spots corresponding to PtdInsP
were extracted and submitted to an in vitro kinase assay using
recombinant PtdIns5P 4-kinase type IIa in presence of [c-32P]-
ATP [28,29]. Among the different PtdInsP species, this kinase
specifically phosphorylates PtdIns5P to PtdIns(4,5)P2 and the
measured quantity of 32P-PtdIns(4,5)P2 will directly represent the
in vivo PtdIns5P intracellular levels. The total lipids from TA
muscles were extracted with the Dounce homogenizer using the
method of Bligh and Dyer [47] and prepared for mass assay to
measure the intracellular PtdnIs3P levels in muscle by a novel
mass assay using recombinant PIKfyve kinase in presence of
[c-32P]-ATP [35].
Figure 10. XLCNM phenotypes that are ameliorated by the MTM1-C375S phosphatase-dead mutant to a similar extend as with the
wild-type MTM1, in the Mtm1 KO muscle. Phosphate-independent and phosphatase-dependent functions are underlined.
doi:10.1371/journal.pgen.1002965.g010
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Production and purification of Adeno-Associated Virus
(rAAV)
rAAV2/1 vectors were generated by a triple transfection of
AAV-293 cell line with pAAV2-insert containing the insert under
the control of the CMV promoter and flanked by serotype-2
inverted terminal repeats, pXR1 containing rep and cap genes of
AAV serotype-1, and pHelper encoding the adenovirus helper
functions. Viral vectors were purified and quantified by real time
PCR using a plasmid standard pAAV-eGFP. Titers are expressed
as viral genomes per ml (vg/ml) and rAAV titers used here were 5–
7.1011 vg/ml.
AAV–transduction of wild-type tibialis anterior muscle of
mice
Two to three week-old male wild-type and Mtm1 KO 129PAS
mice were anesthetized by intraperitoneal injection of 5 ml/body
gram of ketamine (20 mg/ml, Virbac) and xylazine (0.4%,
Rompun, Bayer). Tibialis anterior (TA) muscles were injected
with 20 ml of AAV2/1 preparations, or AAV2/1 empty virus
solution. Animals were housed in a temperature-controlled room
(19–22uC) with a 12:12-h light/dark cycle. Mice were humanely
killed by CO2 inhalation followed by cervical dislocation,
according to national and European legislations on animal
experimentation. TA muscles were dissected 4 weeks after
injection and frozen in nitrogen-cooled isopentane and liquid
nitrogen for histological and immunoblot assays, respectively.
Functional analysis of the muscle
Muscle force measurements were evaluated by measuring in situ
muscle contraction in response to nerve and muscle stimulation, as
described previously. Animals were anesthetized by intraperitoneal
injection of pentobarbital sodium (50 mg per kg). The distal
tendon of the TA was detached and tied with a silk ligature to an
isometric transducer (Harvard Bioscience, Holliston, MA). The
sciatic nerve was distally stimulated, response to tetanic stimulation
(pulse frequency of 50 to 143 Hz) was recorded, and absolute
maximal force was determined. After contractile measurements,
the animals were sacrificed by cervical dislocation. To determine
specific maximal force, TA muscles were dissected and weighted.
Histological and immunofluorescence analysis of skeletal
muscle
Transverse cryosections (8 mm) of mouse TA skeletal muscles
were stained with hematoxylin and eosin (HE), succinate
dehydrogenase (SDH) and viewed with a fluorescence microscope
(DM4000; Leica Microsystems, Sunnyvale, CA). Cross-sectional
area (CSA) was analyzed on HE sections from TA mouse skeletal
muscles, using the RoiManager plugin of ImageJ image analysis
software (Rasband, W.S., ImageJ, U. S. National Institutes of
Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/,
1997–2009). The percentage of TA muscle fibres with centralized
or internalized nuclei was counted using the cell counter plugin of
ImageJ image analysis software. Transverse cryosections (8 mm)
sections of mouse TA skeletal muscles were prepared, fixed, and
stained with antibodies to desmin (Santa Cruz). Nuclei were
detected by co-staining with Hoechst (Sigma-Aldrich) for 10 min-
utes. Sections were viewed using a fluorescence microscope
(DM4000; Leica Microsystems, Sunnyvale, CA).
Transmission electron microscopy
Muscle biopsies from TA muscles of anesthetized mice were
fixed with 4% PFA and 2.5% glutaraldehyde in 0.1 M phosphate
buffer (pH 7.2) and processed as described [30]. Determination of
the triads organization was accomplished on images at the
magnification of 625,000. The triad structure was identified
using morphological criteria on the longitudinal sections of the
muscle and the number of triads per sarcomere was quantified.
Ratio of triads/sarcomere was calculated by dividing number of
triad structure identified by the total number of sarcomere present
on the section.
Microsome preparations
Frozen muscles were homogenized to prepare membranous
(microsomal) fractions from skeletal muscles [32]. Membrane
fractionation was confirmed using several protein markers: mouse
anti-SERCA1 (MA3–911; ABR) and mouse anti-a-sarcoglycan
[48], cytoplasmic protein mouse anti-b-tubulin (IGBMC antibody
facility) and nucleus protein mouse anti-TATA-box-binding
protein (IGBMC antibody facility).
Desmin solubility assays
Cells or muscles were treated as described in [32] with the
following modifications. Extracts were obtained by homogeniza-
tion in extraction buffer (50 mM Tris-Cl pH 7.5, 50 mM NaCl,
5 mM EDTA, 5 mM EGTA, 1 mM DTT, 0,5% Triton X-100,
2 mM PMSF) supplemented with complete protease inhibitor
tablet (Roche), 1 mM Leupeptin and 1 mM pepstatin A (SIGMA).
Equal weight of tibialis anterior muscles were homogenized with a
Polytron homogenizer (Kinematica Inc.) in ice-cold extraction
buffer supplemented with 0.05% (w/v) SDS. The muscle extracts
were incubated ON at 4uC in the extraction buffer with 0.1% of
N-Lauroylsarcosine Sodium Salt solution (SIGMA). Muscle
extracts were centrifuged during 30 min at 30,000 rpm at 4uC.
Pellets were collected as the insoluble material and solubilized in
extraction buffer supplemented with 8 M Urea.
Extended experimental procedures are available in Text S1.
Supporting Information
Figure S1 Analysis of growth upon MTM1 expression in ymr1D
yeast cells. (A) Drop test growth assays on ymr1D mutant yeast cells
transformed or not with pVV204 (CEN, expression) or pVV200
(2 m, overexpression) plasmids bearing the different MTM1
proteins. Mid-log phase cultures of the indicated yeast cells were
serially diluted to the indicated OD600 and spotted onto YPD
medium. Growth was evaluated after 2 days of incubation at 30uC.
(B) Growth curves of ymr1D cells bearing pVV200 (2 m) plasmid
either empty or coding for different MTM1 forms. Cell
concentrations were measured by OD600 nm at the indicated time
after incubation at 30uC. The growth curve corresponds to the
logarithmic curve.
(TIF)
Figure S2 Analysis of vacuolar morphology upon MTM1
expression in wild-type yeast cells. (A) Anti-MTM1 Western-blot
on wild-type yeast protein extracts. Protein extracts of wild-type
yeast cells transformed or not with pVV204 (CEN, expression) or
pVV200 (2mu, overexpression) empty plasmids or bearing the
indicated MTM1 constructs were analyzed by Western-blot with
the monoclonal 1G6 anti-MTM1 antibody. Degradation products
could be seen associated to high expression. (B) Mid-log phase
yeast cells cultures of wild-type (WT) yeast strain transformed or
not with pVV204 (CEN) or pVV200 (2 m) plasmids bearing the
different MTM1 forms were serially diluted to the indicated
OD600 and spotted on YPD plates. Growth was evaluated after 2
days of incubation at 30uC. (C) Quantification of the different
vacuolar morphologies observed in wild-type yeast cells (SEY6210
WT) producing MTM1, MTM1C375S, MTM1V49F, MTM1R69C,
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MTM1N180K or MTM1R421Q on either pVV204 (CEN, expres-
sion) or pVV200 (2 m, overexpression) plasmid. For each strain,
300 to 600 cells were observed by microscopy (DIC and FM4-64)
and sorted into one of the three categories: unilobar large or giant
(in white), small one or two lobes (in grey) and more than two lobes
or fragmented (in black) vacuoles. A scheme representing these
three classes of vacuolar phenotypes is presented at the top of the
graph. Histograms show the proportion of each class in the
different transformed yeast cells.
(TIF)
Figure S3 Subcellular distribution of the different MTM1
mutants. Total yeast protein extracts of ymr1D cells expressing
wild-type MTM1 or the different mutants from pVV204 (CEN)
were subjected to differential centrifugation. P13 and P100 pellet
fractions represent the high-density membrane fractions, and the
supernatant S100 the soluble fraction. Equivalent amounts of
proteins were loaded, separated by SDS-PAGE and analyzed by
western-blot. MTM1 was detected with mouse monoclonal 1G6
antibodies. The transmembrane sorting receptor Vps10 and the
cytosolic 3-phosphoglycerate kinase Pgk1 were used as markers.
(TIF)
Figure S4 In vitro phosphatase activity assays on the different
MTM1 mutants. Yeast protein extracts from ymr1D cells
transformed with pVV200 (overexpression) plasmid either empty
or coding for wild type MTM1 protein or the different mutants
were subjected to anti-MTM1 immunoprecipitation. After control
by anti-MTM1 Western-blot, comparable amounts of MTM1
were tested for in vitro phosphatase activity using fluorescent C6-
BODIPY-FL-PPIn, according to [49] and [28]. (A) The products
of the enzymatic reaction were separated by TLC (Thin Layer
Chromatography) allowing the different PPIn species (PtdIns,
PtdIns monophosphate and PtdIns bisphosphate) to migrate at a
different height. Fluorescent PtdIns, PtdIns3P, PtdIns5P (barely
detectable) and PtdIns(3,5)P2 were spotted on the TLC and used as
controls for the TLC migration (phosphoinositides). The TLC
plate was revealed under a UV table. (B) Percentage of hydrolysis
of the fluorescent phosphoinositide substrates (PtdIns3P in blue
and PtdIns(3,5)P2 in red) are reported for each construct.
(TIF)
Figure S5 Model of MTM1-C375S and MTM1-S376N. The
crystal structure of MTMR2 (PDB accession number 1ZSQ) was
used to model the MTM1 catalytic pocket that shares the same
amino acids. The figure was prepared with the PyMOL software
(The PyMOL Molecular Graphics System, Version 1.5.0.1
Schro¨dinger, LLC.). (A) MTM1-C375S model. (B) MTM1-
S376N model. (C) The MTM1-S376N mutant is catalytically
inactive in vivo in yeast cells. Protein extracts of ymr1D cells
transformed with pVV204 (CEN) or pVV200 (2 m) plasmids
bearing the MTM1-S376N mutant were analyzed by Western-
blot. MTM1 production was detected with the mouse monoclonal
1G6 anti-MTM1 antibody. Protein loading was evaluated by
immunodetection of the yeast endogenous 3-phosphoglycerate
kinase Pgk1 protein. (D) Quantification of the different vacuolar
morphologies observed in ymr1D yeast cells producing MTM1,
MTM1C375S or MTM1S376N on pVV200 (2 m, overexpression)
plasmid. For each strain, 300 to 500 cells were observed by
microscopy (DIC and FM4-64) and sorted into one of the three
categories: unilobar large or giant (in white), small one or two lobes
(in grey) and more than two lobes or fragmented (in black)
vacuoles. Histograms show the proportion of each class in the
different transformed yeast cells. (E) Quantitative analysis of
PtdIns5P produced in ymr1D cells transformed with the pVV204
(CEN, expression) plasmid empty or bearing MTM1 wild-type,
MTM1-C375S or MTM1-S376N mutant. The intracellular levels
of PtdIns5P are expressed as pmol for 200 units of OD600 nm of
yeast cells. The graphs represent the mean of two independent
experiments shown with the standard deviation.
(TIF)
Text S1 Extended experimental procedures.
(PDF)
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